Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018801 (
heart failure
)
72,216
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Chinese patent medicine
Tongxinluo capsule
(
TXL
) is commonly used for cardio-cerebrovascular diseases. Previous research had demonstrated that
TXL
exhibited great clinical effects on the treatment of acute myocardial infarction (AMI), however there is a lack of systematic review. The purpose of this study was to evaluate the potential effectiveness and safety of
TXL
for secondary prevention in patients with AMI.
Method:
We searched 6 databases to identify relevant randomized controlled trials (RCTs) from inceptions to December 30, 2017. Two review authors independently assessed the methodological quality and analyzed data by the RevMan 5.3 software. The publication bias was assessed through funnel plot and Begg's test. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used for evaluating the quality of evidence.
Results:
We included 19 RCTs in this review and performed a meta-analysis based on 16 studies. There were statistical differences of
TXL
treatment group in reducing primary cardiovascular events (cardiac death [RR = 0.27, 95%CI: 0.08~0.95,
I
2
= 0%], recurrent myocardial reinfarction [RR = 0.38, 95%CI: 0.20~0.74,
I
2
= 0%], arrhythmia [RR = 0.44, 95%CI: 0.30~0.66,
I
2
= 0%], recurrent angina pectoris [RR = 0.34, 95%CI: 0.17~0.69,
I
2
= 0%]).
TXL
could improve cardiac function (LVEF [MD = 4.10, 95%CI: 3.95~4.25,
I
2
= 0%]), regulate blood lipid TC [MD = -0.66, 95%CI: -0.94 ~ -0.37,
I
2
= 74%], TG [MD = -0.38, 95%CI: -0.62 ~ -0.14, I
2
= 70%], LDL-C[-0.40, 95%CI: -0.65 ~ -0.16,
I
2
= 88%), decrease the level of hs-CRP (4-week: MD = -0.78, 95%CI: -0.97 ~ -0.60,
I
2
= 20%; Over 4-week: MD = -1.36, 95%CI: -1.55 ~ -1.17,
I
2
= 20%). However,
TXL
has little effects on revascularization [RR = 0.45, 95%CI: 0.13~1.56,
I
2
= 0%], recurrent
heart failure
(RR = 0.83, 95%CI: 0.27~2.57,
I
2
= 0%), and HDL-C (MD = 0.14, 95%CI: 0.00 ~0.29,
I
2
= 73%). Furthermore,
TXL
treatment group was more prone to suffer gastrointestinal discomfort.
Conclusion:
Chinese patent medicine
TXL
seemed beneficial for secondary prevention after AMI. This potential benefit needs to be further assessed through more rigorous RCTs. Systematic review registration number in the PROSPERO register: CRD42017068417.
...
PMID:Potential Effectiveness of Chinese Patent Medicine
Tongxinluo Capsule
for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 3012 26
